undamentalytics Newsletter
Sign in

Harmony Biosciences Holdings, Inc. cash flow statement

In fiscal 2025, Harmony Biosciences Holdings, Inc.'s operations generated $348m of cash; it spent $310,000 on capital projects, leaving free cash flow of $348m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−75−399144219220348355
Depreciation and amortisation000010——
Stock-based pay105162632434541
Capital spending00000100
Free cash flow−76−398144219219348355
Free cash flow after stock pay−85−883118187176303314
Share buybacks—0——100———
Shares issued—13530—————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ANIP vs HRMYAXSM vs HRMYHRMY vs SUPNHRMY vs PBH

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Harmony Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Harmony Biosciences Holdings, Inc.